Tvardi Therapeutics, Inc.
TVRD
$1.89
-$0.06-2.84%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.53% | 93.73% | 96.03% | 200.68% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.40% | 5.11% | -4.84% | 36.39% | -- |
| Operating Income | 8.40% | -5.11% | 4.84% | -36.39% | -- |
| Income Before Tax | -10.29% | 55.60% | 38.04% | -12.38% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.29% | 55.60% | 38.04% | -12.38% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.29% | 55.60% | 38.04% | -12.38% | -- |
| EBIT | 8.40% | -5.11% | 4.84% | -36.39% | -- |
| EBITDA | 8.43% | -5.13% | 4.85% | -36.55% | -- |
| EPS Basic | 73.00% | 88.26% | 56.15% | -41.18% | -- |
| Normalized Basic EPS | 73.00% | 88.26% | 56.15% | -41.19% | -- |
| EPS Diluted | 76.44% | 77.09% | 41.72% | -65.62% | -- |
| Normalized Diluted EPS | 73.03% | 88.17% | 56.03% | -41.39% | -- |
| Average Basic Shares Outstanding | 134.92% | 253.26% | 109.51% | 27.07% | -- |
| Average Diluted Shares Outstanding | 131.89% | 255.29% | 110.99% | 28.24% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |